Physician profile
Edward P Case
NPI 1407808785
$14,705.53
in general payments reported to CMS, 2019-2025
20 companies · $6,634 in 2025
The $6,634 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $725 · 2021: $1,828 · 2022: $1,092 · 2023: $2,796 · 2024: $773 · 2025: $6,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,180 · Food and Beverage: $3,427 · Consulting Fee: $360 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,180.00 |
| Food and Beverage | $3,427.21 |
| Consulting Fee | $360.00 |
| Education | $235.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,151.91 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Corium, LLC | $2,443.14 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $760.70 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $757.34 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $748.52 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $650.90 | 2019-2022 | |
| Allergan, INC. | $576.09 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $482.61 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $422.42 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $420.25 | 2022-2025 | Auvelity |
| Lundbeck LLC | $413.42 | 2019-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $256.43 | 2019-2022 | |
| Alkermes, INC. | $234.12 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $149.48 | 2019-2021 | |
| Indivior INC. | $87.86 | 2023-2025 | Sublocade, Perseris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $55.48 | 2019 | |
| Jazz Pharmaceuticals INC. | $54.72 | 2021 | |
| Merck Sharp & Dohme LLC | $14.46 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.